S&P 500   5,068.20 (-0.03%)
DOW   38,921.87 (-0.38%)
QQQ   437.11 (+0.13%)
AAPL   180.96 (-0.11%)
MSFT   406.05 (-0.37%)
META   484.37 (+0.55%)
GOOGL   138.15 (+0.42%)
AMZN   174.02 (-0.41%)
TSLA   201.64 (+1.12%)
NVDA   786.50 (-0.56%)
NIO   5.75 (+1.77%)
AMD   177.01 (+0.57%)
BABA   77.60 (+1.42%)
T   16.64 (+0.24%)
F   12.01 (+0.50%)
MU   90.87 (+1.58%)
CGC   3.51 (+1.15%)
GE   153.68 (-0.70%)
DIS   108.29 (+0.57%)
AMC   4.64 (+4.27%)
PFE   26.98 (-0.74%)
PYPL   59.61 (+0.47%)
XOM   104.20 (-0.05%)
S&P 500   5,068.20 (-0.03%)
DOW   38,921.87 (-0.38%)
QQQ   437.11 (+0.13%)
AAPL   180.96 (-0.11%)
MSFT   406.05 (-0.37%)
META   484.37 (+0.55%)
GOOGL   138.15 (+0.42%)
AMZN   174.02 (-0.41%)
TSLA   201.64 (+1.12%)
NVDA   786.50 (-0.56%)
NIO   5.75 (+1.77%)
AMD   177.01 (+0.57%)
BABA   77.60 (+1.42%)
T   16.64 (+0.24%)
F   12.01 (+0.50%)
MU   90.87 (+1.58%)
CGC   3.51 (+1.15%)
GE   153.68 (-0.70%)
DIS   108.29 (+0.57%)
AMC   4.64 (+4.27%)
PFE   26.98 (-0.74%)
PYPL   59.61 (+0.47%)
XOM   104.20 (-0.05%)
S&P 500   5,068.20 (-0.03%)
DOW   38,921.87 (-0.38%)
QQQ   437.11 (+0.13%)
AAPL   180.96 (-0.11%)
MSFT   406.05 (-0.37%)
META   484.37 (+0.55%)
GOOGL   138.15 (+0.42%)
AMZN   174.02 (-0.41%)
TSLA   201.64 (+1.12%)
NVDA   786.50 (-0.56%)
NIO   5.75 (+1.77%)
AMD   177.01 (+0.57%)
BABA   77.60 (+1.42%)
T   16.64 (+0.24%)
F   12.01 (+0.50%)
MU   90.87 (+1.58%)
CGC   3.51 (+1.15%)
GE   153.68 (-0.70%)
DIS   108.29 (+0.57%)
AMC   4.64 (+4.27%)
PFE   26.98 (-0.74%)
PYPL   59.61 (+0.47%)
XOM   104.20 (-0.05%)
S&P 500   5,068.20 (-0.03%)
DOW   38,921.87 (-0.38%)
QQQ   437.11 (+0.13%)
AAPL   180.96 (-0.11%)
MSFT   406.05 (-0.37%)
META   484.37 (+0.55%)
GOOGL   138.15 (+0.42%)
AMZN   174.02 (-0.41%)
TSLA   201.64 (+1.12%)
NVDA   786.50 (-0.56%)
NIO   5.75 (+1.77%)
AMD   177.01 (+0.57%)
BABA   77.60 (+1.42%)
T   16.64 (+0.24%)
F   12.01 (+0.50%)
MU   90.87 (+1.58%)
CGC   3.51 (+1.15%)
GE   153.68 (-0.70%)
DIS   108.29 (+0.57%)
AMC   4.64 (+4.27%)
PFE   26.98 (-0.74%)
PYPL   59.61 (+0.47%)
XOM   104.20 (-0.05%)

argenx (ARGX) Stock Price, News & Analysis

$407.28
-3.07 (-0.75%)
(As of 11:12 AM ET)
Today's Range
$406.25
$409.75
50-Day Range
$338.91
$452.58
52-Week Range
$327.73
$550.76
Volume
52,520 shs
Average Volume
360,516 shs
Market Capitalization
$24.11 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$526.29

argenx MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
28.3% Upside
$526.29 Price Target
Short Interest
Healthy
2.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.79mentions of argenx in the last 14 days
Based on 18 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.91) to ($2.53) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.75 out of 5 stars

Medical Sector

240th out of 942 stocks

Biological Products, Except Diagnostic Industry

34th out of 152 stocks


ARGX stock logo

About argenx Stock (NASDAQ:ARGX)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

ARGX Stock Price History

ARGX Stock News Headlines

5 medical stocks growing earnings by triple digits (ARGX)
There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
argenx to Present at Upcoming Investor Conferences
ARGX Mar 2024 400.000 put
argenx Stock (NASDAQ:ARGX), Short Interest Report
Argenx Is Tracking Well Above the Industry
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
argenx (ARGX) to Release Earnings on Thursday
Argenx's VYVGART Hytrulo Granted Priority Review By FDA For CIDP
argenx (NASDAQ:ARGX) Coverage Initiated at Wolfe Research
Oppenheimer Reaffirms Their Hold Rating on Argenx Se (ARGX)
Argenx SE (ARGX) Declined on Failed Clinical Trials
How Argenx (ARGX) Stock Stands Out in a Strong Industry
See More Headlines
Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/31/2023
Today
2/27/2024
Next Earnings (Confirmed)
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ARGX
Fax
N/A
Employees
843
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$526.29
High Stock Price Target
$641.00
Low Stock Price Target
$346.00
Potential Upside/Downside
+28.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
22 Analysts

Profitability

Net Income
$-709,590,000.00
Pretax Margin
-27.55%

Debt

Sales & Book Value

Annual Sales
$993.64 million
Book Value
$50.79 per share

Miscellaneous

Free Float
57,756,000
Market Cap
$24.29 billion
Optionable
Optionable
Beta
0.69
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Timothy Van Hauwermeiren EMBA (Age 52)
    M.B.A., M.Sc., CEO & Executive Director
    Comp: $1.44M
  • Mr. Karl Gubitz (Age 54)
    Chief Financial Officer
  • Ms. Malini Moorthy (Age 54)
    General Counsel
  • Mr. Arjen Lemmen M.Sc. (Age 39)
    Vice President of Corporate Development & Strategy
  • Ms. Andria Wilk (Age 50)
    Global Head of Quality
  • Mr. Luc Truyen (Age 59)
    Chief Medical Officer
  • Ms. Karen Massey (Age 45)
    Chief Operating Officer
  • Mr. Filip Borgions
    VP & Global Head of Technical Operations
  • Mr. Peter Ulrichts (Age 44)
    Chief Scientific Officer
  • Ms. Beth DelGiacco
    VP and Global Head of Corporate Communications & Investor Relations

Should I Buy argenx Stock? ARGX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of argenx was last updated on Tuesday, February 20, 2024 at 10:19 PM.














ARGX Stock Analysis - Frequently Asked Questions

Should I buy or sell argenx stock right now?

22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 1 sell rating, 5 hold ratings, 15 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARGX shares.
View ARGX analyst ratings
or view top-rated stocks.

What is argenx's stock price target for 2024?

22 Wall Street analysts have issued 12 month price objectives for argenx's shares. Their ARGX share price targets range from $346.00 to $641.00. On average, they predict the company's stock price to reach $526.29 in the next twelve months. This suggests a possible upside of 28.3% from the stock's current price.
View analysts price targets for ARGX
or view top-rated stocks among Wall Street analysts.

How have ARGX shares performed in 2024?

argenx's stock was trading at $380.43 at the beginning of the year. Since then, ARGX shares have increased by 7.9% and is now trading at $410.35.
View the best growth stocks for 2024 here
.

Are investors shorting argenx?

argenx saw a decline in short interest in January. As of January 31st, there was short interest totaling 1,190,000 shares, a decline of 13.1% from the January 15th total of 1,370,000 shares. Based on an average daily volume of 464,400 shares, the short-interest ratio is currently 2.6 days.
View argenx's Short Interest
.

When is argenx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 29th 2024.
View our ARGX earnings forecast
.

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) released its quarterly earnings results on Tuesday, October, 31st. The company reported ($1.25) earnings per share for the quarter, topping analysts' consensus estimates of ($1.48) by $0.23. The firm had revenue of $339.84 million for the quarter, compared to analysts' expectations of $310.06 million. argenx had a negative trailing twelve-month return on equity of 16.54% and a negative net margin of 22.70%. During the same period in the prior year, the firm posted ($4.26) earnings per share.

What guidance has argenx issued on next quarter's earnings?

argenx issued an update on its fourth quarter 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $374.0 million-$374.0 million, compared to the consensus revenue estimate of $358.9 million.

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?

(ARGX) raised $65 million in an initial public offering on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are argenx's major shareholders?

argenx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (6.21%), Artisan Partners Limited Partnership (5.36%), Capital World Investors (3.31%), Avoro Capital Advisors LLC (2.09%), Bellevue Group AG (1.47%) and RTW Investments LP (1.13%).

How do I buy shares of argenx?

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARGX) was last updated on 2/27/2024 by MarketBeat.com Staff